|
US5120722A
(en)
|
1984-02-08 |
1992-06-09 |
Hoffmann-La Roche Inc. |
Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
|
|
US4857518A
(en)
|
1984-10-04 |
1989-08-15 |
Wisconsin Alumni Research Foundation |
Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
|
|
US4717721A
(en)
|
1985-05-30 |
1988-01-05 |
Howard W. Bremer |
Sidechain homo-vitamin D compounds with preferential anti-cancer activity
|
|
WO1987000834A1
(en)
|
1985-08-02 |
1987-02-12 |
Leo Pharmaceutical Products Ltd. A/S |
Novel vitamin d analogues
|
|
US5145846A
(en)
|
1988-01-20 |
1992-09-08 |
Hoffmann-La Roche Inc. |
Vitamin D3 analogs
|
|
US4851401A
(en)
|
1988-07-14 |
1989-07-25 |
Wisconsin Alumni Research Foundation |
Novel cyclopentano-vitamin D analogs
|
|
CA1333616C
(en)
|
1989-03-09 |
1994-12-20 |
Hector F. Deluca |
19-nor-vitamin d compounds
|
|
GB8915770D0
(en)
|
1989-07-10 |
1989-08-31 |
Leo Pharm Prod Ltd |
Chemical compounds
|
|
US4966898A
(en)
|
1989-08-15 |
1990-10-30 |
Merrell Dow Pharmaceuticals Inc. |
4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
|
|
DE4021433A1
(de)
|
1990-07-04 |
1992-01-09 |
Schering Ag |
Antiandrogene mit steroid(3,2-c)pyrazol-struktur
|
|
DE4101953A1
(de)
|
1991-01-19 |
1992-07-23 |
Schering Ag |
23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
|
|
DE4141746A1
(de)
|
1991-12-13 |
1993-06-17 |
Schering Ag |
20-methyl-substituierte vitamin d-derivate
|
|
US5604213A
(en)
|
1992-03-31 |
1997-02-18 |
British Technology Group Limited |
17-substituted steroids useful in cancer treatment
|
|
ES2138618T3
(es)
|
1992-03-31 |
2000-01-16 |
Btg Int Ltd |
Esteroides 17-sustituidos utiles en el tratamiento del cancer.
|
|
US5547947A
(en)
|
1993-03-11 |
1996-08-20 |
Hoffmann-La Roche Inc. |
Methods of treatment
|
|
ES2127413T3
(es)
|
1993-09-30 |
1999-04-16 |
Btg Int Ltd |
Sintesis de esteroides 17-(3-piridilo).
|
|
US5688977A
(en)
|
1996-02-29 |
1997-11-18 |
Napro Biotherapeutics, Inc. |
Method for docetaxel synthesis
|
|
US5795909A
(en)
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
|
US5919815A
(en)
|
1996-05-22 |
1999-07-06 |
Neuromedica, Inc. |
Taxane compounds and compositions
|
|
EP0914116B1
(en)
|
1996-05-22 |
2000-10-11 |
Protarga Inc. |
Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
|
|
GB9622590D0
(en)
|
1996-10-30 |
1997-01-08 |
Leo Pharm Prod Ltd |
Chemical compounds
|
|
US20020128240A1
(en)
|
1996-12-30 |
2002-09-12 |
Bone Care International, Inc. |
Treatment of hyperproliferative diseases using active vitamin D analogues
|
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
|
US20050233958A1
(en)
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
|
US6087350A
(en)
|
1997-08-29 |
2000-07-11 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
|
|
JP2002509888A
(ja)
|
1998-03-27 |
2002-04-02 |
オレゴン ヘルス サイエンシーズ ユニバーシティー |
腫瘍および他の過増殖性疾患の治療におけるビタミンｄおよびその類似体
|
|
US20030083231A1
(en)
|
1998-11-24 |
2003-05-01 |
Ahlem Clarence N. |
Blood cell deficiency treatment method
|
|
WO2000038715A2
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle & Co. |
Use of an integrin antagonist and radiation in the treatment of neoplasia
|
|
CA2401304A1
(en)
|
2000-03-02 |
2001-09-07 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Combination chemotherapy
|
|
JPWO2001081364A1
(ja)
|
2000-04-24 |
2004-01-08 |
協和醗酵工業株式会社 |
エストラ−１，３，５（１０）−トリエン誘導体
|
|
NZ522767A
(en)
|
2000-05-15 |
2004-07-30 |
Celgene Corp |
Thalidomide and a topoisomerase inhibitor for the treatment of cancer
|
|
EP1676577A1
(en)
|
2000-05-15 |
2006-07-05 |
Celgene Corporation |
Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide
|
|
CN1981873A
(zh)
|
2000-06-09 |
2007-06-20 |
莱古伦公司 |
制备微胶粒的方法和所述微胶粒的用途
|
|
WO2002003286A1
(en)
|
2000-07-05 |
2002-01-10 |
Bryan Muehlberger |
Systems and methods of facilitating electronic payment transactions
|
|
US6960590B2
(en)
|
2000-10-17 |
2005-11-01 |
Merck & Co. Inc. |
Orally active salts with tyrosine kinase activity
|
|
US6750213B2
(en)
|
2000-10-19 |
2004-06-15 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
DE10061137B4
(de)
|
2000-12-07 |
2016-10-06 |
Takeda Gmbh |
Neue pharmazeutische Zubereitung
|
|
EP1351678A2
(en)
|
2001-01-02 |
2003-10-15 |
Elizabeth Shanahan-Prendergast |
Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
|
|
ATE410165T1
(de)
|
2001-04-18 |
2008-10-15 |
Euro Celtique Sa |
Nociceptin-analoga
|
|
EP2033644A1
(en)
|
2001-04-18 |
2009-03-11 |
Euro-Celtique S.A. |
Spiroindene and spiroindane compounds
|
|
CN1516584A
(zh)
|
2001-04-18 |
2004-07-28 |
ŷ�����ǹɷ�����˾ |
螺吡唑化合物
|
|
ATE403431T1
(de)
|
2001-04-18 |
2008-08-15 |
Euro Celtique Sa |
Benzimidazolon-verbindungen
|
|
US6838584B2
(en)
|
2001-05-10 |
2005-01-04 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
WO2004016753A2
(en)
|
2002-08-15 |
2004-02-26 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
|
US20040171630A1
(en)
|
2001-06-19 |
2004-09-02 |
Yuntae Kim |
Tyrosine kinase inhibitors
|
|
US6740641B2
(en)
|
2001-07-27 |
2004-05-25 |
Euro-Celtique, S.A. |
Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
|
|
WO2003020699A2
(en)
|
2001-08-30 |
2003-03-13 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
MY141661A
(en)
|
2001-09-06 |
2010-05-31 |
Schering Corp |
17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
|
|
WO2003037252A2
(en)
|
2001-10-30 |
2003-05-08 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
CA2465491A1
(en)
|
2001-11-07 |
2003-05-15 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
|
ATE372341T1
(de)
|
2001-12-06 |
2007-09-15 |
Merck & Co Inc |
Inhibitoren von mitotischem kinesin
|
|
WO2005016236A2
(en)
|
2003-05-06 |
2005-02-24 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
|
AU2003212882A1
(en)
|
2002-02-01 |
2003-09-02 |
Euro-Celtique S.A. |
2 - piperazine - pyridines useful for treating pain
|
|
EP1336602A1
(en)
|
2002-02-13 |
2003-08-20 |
Giovanni Scaramuzzino |
Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
|
|
US6974818B2
(en)
|
2002-03-01 |
2005-12-13 |
Euro-Celtique S.A. |
1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
|
|
WO2003075958A1
(fr)
|
2002-03-11 |
2003-09-18 |
Takeda Chemical Industries, Ltd. |
Medicaments permettant de traiter une maladie dependant d'une hormone sexuelle
|
|
WO2003086404A1
(en)
|
2002-04-08 |
2003-10-23 |
Merck & Co., Inc. |
Fused quinoxaline derivatives as inhibitors of akt activity
|
|
EP1927858B1
(en)
|
2002-04-29 |
2013-01-09 |
Euro-Celtique S.A. |
Conformationally constrained peptides that bind the ORL-1 receptor
|
|
US7125888B2
(en)
|
2002-05-02 |
2006-10-24 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
AU2003276005B2
(en)
|
2002-06-14 |
2009-01-15 |
Merck Sharp & Dohme Corp. |
Mitotic kinesin inhibitors
|
|
DE60318875T2
(de)
|
2002-06-28 |
2009-01-15 |
Euro-Celtique S.A. |
Therapeutische piperazin-derivate für die behandlung von schmerzen
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
US20050101581A1
(en)
|
2002-08-28 |
2005-05-12 |
Reading Christopher L. |
Therapeutic treatment methods 2
|
|
WO2004019953A1
(en)
|
2002-08-28 |
2004-03-11 |
Hollis-Eden Pharmaceuticals, Inc. |
Therapeutic treatment methods
|
|
US7157462B2
(en)
|
2002-09-24 |
2007-01-02 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
WO2004037269A1
(en)
|
2002-10-23 |
2004-05-06 |
Pantarhei Bioscience B.V. |
Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
|
|
EP1558609A4
(en)
|
2002-10-30 |
2008-05-28 |
Merck & Co Inc |
KINASE INHIBITORS
|
|
US7202259B2
(en)
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
AU2003293555A1
(en)
|
2002-12-17 |
2004-07-29 |
Schering Corporation |
17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
|
|
US7582635B2
(en)
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
|
EP1583539A2
(en)
|
2003-01-13 |
2005-10-12 |
Cedars-Sinai Medical Center |
Paricalcitol as a chemotherapeutic agent
|
|
TWI330079B
(en)
|
2003-01-15 |
2010-09-11 |
Synta Pharmaceuticals Corp |
Treatment for cancers
|
|
US20050020546A1
(en)
|
2003-06-11 |
2005-01-27 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
|
AR044688A1
(es)
|
2003-06-12 |
2005-09-21 |
Euro Celtique Sa |
Agentes terapeuticos utiles para el tratamiento del dolor
|
|
ES2327684T3
(es)
|
2003-07-24 |
2009-11-02 |
Euro-Celtique S.A. |
Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor.
|
|
PL1867644T3
(pl)
|
2003-07-24 |
2009-10-30 |
Euro Celtique Sa |
Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
|
|
US7071333B2
(en)
|
2003-07-30 |
2006-07-04 |
Bristol-Myers Squibb Company |
Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
|
|
MXPA06001331A
(es)
|
2003-08-01 |
2006-05-04 |
Euro Celtique Sa |
Agentes terapeuticos utiles para el tratamiento del dolor.
|
|
US20060287402A1
(en)
|
2003-08-27 |
2006-12-21 |
Christopher Bayly |
Cathepsin inhibitors
|
|
MXPA06003123A
(es)
|
2003-09-22 |
2006-05-31 |
Euro Celtique Sa |
Agentes terapeuticos utiles para el tratamiento del dolor.
|
|
SI1664041T1
(sl)
|
2003-09-22 |
2008-12-31 |
Euro Celtique Sa |
Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
|
|
PT1673092E
(pt)
|
2003-10-17 |
2007-11-23 |
4 Aza Ip Nv |
''derivados de pteridina substituídos com heterociclos e sua utilização em terapia''
|
|
WO2005107801A2
(en)
|
2004-04-29 |
2005-11-17 |
The Regents Of The University Of Colorado |
Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies
|
|
US20060003950A1
(en)
|
2004-06-30 |
2006-01-05 |
Bone Care International, Inc. |
Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
|
|
US7094775B2
(en)
|
2004-06-30 |
2006-08-22 |
Bone Care International, Llc |
Method of treating breast cancer using a combination of vitamin D analogues and other agents
|
|
US20060030608A1
(en)
|
2004-08-04 |
2006-02-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Anti aromatase compounds pharmaceutical compositions and uses thereof
|
|
GB0418900D0
(en)
|
2004-08-24 |
2004-09-29 |
Btg Int Ltd |
Novel salt forms
|
|
CA2579732C
(en)
|
2004-09-10 |
2014-08-12 |
Nitec Pharma Ag |
Tablets with site time-controlled gastrointestinal release of active ingredient
|
|
AR051597A1
(es)
|
2004-11-01 |
2007-01-24 |
Merck & Co Inc |
Moduladores de los receptores de estrogeno
|
|
EP1674479A1
(en)
|
2004-12-22 |
2006-06-28 |
Memorial Sloan-Kettering Cancer Center |
Modulation of Fc Gamma receptors for optimizing immunotherapy
|
|
WO2006081152A2
(en)
|
2005-01-24 |
2006-08-03 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
JP2008539276A
(ja)
|
2005-04-27 |
2008-11-13 |
ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド |
ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法
|
|
EP1877060A2
(en)
|
2005-04-28 |
2008-01-16 |
The Regents of the University of Colorado |
Therapeutic bifunctional compounds
|
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
|
CN101267779A
(zh)
|
2005-07-27 |
2008-09-17 |
福罗里达大学研究基金会有限公司 |
使用热休克治疗眼睛疾病
|
|
US20090275619A1
(en)
|
2006-04-03 |
2009-11-05 |
BOUERES Julia |
Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
|
|
AU2007300734A1
(en)
|
2006-06-02 |
2008-04-03 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
RNA nanoparticles and nanotubes
|
|
CA2656393A1
(en)
|
2006-06-30 |
2008-01-10 |
Schering Corporation |
Method of using substituted piperidines that increase p53 activity
|
|
WO2008005268A1
(en)
|
2006-06-30 |
2008-01-10 |
Schering Corporation |
Substituted piperidines that increase p53 activity and the uses thereof
|
|
HRP20130961T1
(hr)
|
2006-08-25 |
2013-11-22 |
Janssen Oncology, Inc. |
Kombinacije za tretman raka
|
|
US20080051375A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
|
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
|
EP2081964A4
(en)
|
2006-10-12 |
2012-07-11 |
Univ Johns Hopkins |
ALGINATE AND ALGINATLYASE COMPOSITIONS AND USE METHOD
|
|
EP2081565A2
(en)
|
2006-10-13 |
2009-07-29 |
Reliance Life Sciences Pvt., Ltd. |
Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
|
|
BRPI0806245B1
(pt)
|
2007-01-10 |
2022-01-25 |
Msd Italia S.R.L. |
Compostos de fórmula i e seus usos
|
|
CA2677651A1
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
|
WO2008109740A2
(en)
|
2007-03-06 |
2008-09-12 |
Colby Pharmaceutical Company |
Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
|
|
US20090124587A1
(en)
|
2007-07-12 |
2009-05-14 |
Auerbach Alan H |
METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
|
EP2240466B1
(en)
*
|
2008-01-08 |
2015-07-29 |
Merck Sharp & Dohme Limited |
Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
|
|
ES2480994T3
(es)
|
2008-03-31 |
2014-07-29 |
Genentech, Inc. |
Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
|
|
DK2278975T3
(en)
|
2008-05-07 |
2016-12-19 |
Cardioxyl Pharmaceuticals Inc |
NOVEL nitroso compounds WHICH NITROXYLDONORER AND METHODS OF USE THEREOF
|
|
WO2012009475A1
(en)
|
2010-07-14 |
2012-01-19 |
Oregon Health & Science University |
Methods of treating cancer with inhibition of lysine-specific demethylase 1
|
|
US8658128B2
(en)
|
2011-02-03 |
2014-02-25 |
Pop Test Cortisol Llc |
System and method for diagnosis and treatment
|
|
US9314473B2
(en)
|
2011-02-03 |
2016-04-19 |
Pop Test Oncology Limited Liability Company |
System and method for diagnosis and treatment
|
|
WO2014052237A1
(en)
*
|
2012-09-26 |
2014-04-03 |
Aragon Pharmaceuticals, Inc. |
Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
|
|
WO2014089324A1
(en)
|
2012-12-07 |
2014-06-12 |
Calitor Sciences, Llc |
Substituted cyclic compounds and methods of use
|
|
US9797771B2
(en)
|
2013-03-21 |
2017-10-24 |
Isp Investments Inc. |
Diacetylene film sensitized with photoinitiator and applications of the film
|
|
US9192609B2
(en)
|
2013-04-17 |
2015-11-24 |
Hedgepath Pharmaceuticals, Inc. |
Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
|
|
KR20160058774A
(ko)
*
|
2013-08-12 |
2016-05-25 |
토카이 파마슈티컬, 아이엔씨. |
안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
|
|
WO2015164586A1
(en)
|
2014-04-23 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Targeting parp1 for treatment of tsc and cancers
|
|
US20150344968A1
(en)
|
2014-05-30 |
2015-12-03 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Methods for determining parp inhibitor and platinum resistance in cancer therapy
|
|
US20160160294A1
(en)
|
2014-12-08 |
2016-06-09 |
Tesaro |
Methods and materials for predicting response to niraparib
|
|
US9598459B2
(en)
|
2015-08-03 |
2017-03-21 |
Pop Test Oncology Llc |
Pharmaceutical compositions and methods
|
|
WO2018023017A1
(en)
|
2016-07-29 |
2018-02-01 |
Janssen Pharmaceutica Nv |
Methods of treating prostate cancer
|
|
US11702443B2
(en)
|
2016-10-04 |
2023-07-18 |
Pop Test Oncology Llc |
Therapeutic agents and methods
|
|
WO2018067520A2
(en)
|
2016-10-04 |
2018-04-12 |
Pop Test Oncology Llc |
Therapeutic agents and methods:
|
|
EA201992430A1
(ru)
|
2017-04-13 |
2020-02-28 |
Янссен Фармацевтика Нв |
Комбинированная терапия рака предстательной железы
|
|
JOP20200072A1
(ar)
|
2017-10-11 |
2020-04-29 |
Janssen Oncology Inc |
طرق علاج سرطان البروستاتا من خلال إعطاء أسيتات الأبيراتيرون إلى جانب البريدنيزون مع المعالجة بحرمان الأندروجين
|